Vecura
定价
联系我们
Vecura

产品

  • 定价

公司

  • 联系我们

资源

  • 博客
  • 社区

法律条款

  • 隐私政策
  • 服务条款
  • 信任中心

© 2026 NYB AI 保留所有权利。

所有系统运行正常
Vecura
定价
联系我们
返回博客

Accelerate Your Lead Discovery: ADMET-AI Now Integrated into Vecura

This update empowers medicinal chemists and drug discovery scientists to rapidly evaluate the pharmacokinetic and toxicity profiles of small molecules directly within Vecura, streamlining the lead optimization process without the need for manual model deployment.

May 12, 2026ADMET-AI
ADMET-AI
ADMET-AI is now available on Vecura
vecura.com

What is ADMET-AI?

ADMET-AI is an open-source machine learning platform designed to predict over 30 absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties for small molecules. It utilizes powerful Chemprop v2 message-passing neural networks and RDKit-derived physicochemical descriptors to analyze molecular structures provided as SMILES strings. By leveraging data from the Therapeutics Data Commons (TDC) benchmarks, the tool provides rapid, accurate, and insightful pharmacokinetic analysis in approximately 200 milliseconds per compound.

What can users do with ADMET-AI on Vecura?

With ADMET-AI on Vecura, users can:

  • Instantly predict a comprehensive panel of over 30 ADMET properties for a single molecule or a batch of compounds.
  • Contextualize candidate molecules by comparing their predicted values against the DrugBank approved drug set.
  • Access actionable lead-optimization guidance through percentile ranking scores.
  • Screen chemical libraries efficiently without managing complex, independent technical infrastructure.

What the output means

The output provides a structured JSON object containing predicted values for each ADMET endpoint, including probability scores for classification tasks and real-valued outputs for regression tasks. Furthermore, the model provides a 0–100 percentile rank for each endpoint relative to approved drugs, helping researchers instantly understand the drug-likeness of their candidates.

This output should be used to support scientific decision making. It does not replace experimental validation.

Why this matters

The early-stage evaluation of pharmacokinetic and toxicity profiles is a significant bottleneck in drug discovery. Traditionally, assessing these properties requires extensive and costly in-vitro or in-vivo assays. ADMET-AI helps streamline this process by acting as an "in-silico filter," allowing researchers to prioritize promising chemical scaffolds and eliminate compounds with unfavorable profiles early in the development cycle.

By providing rapid, contextualized feedback, ADMET-AI enables more informed decision-making, ultimately increasing the efficiency of the lead optimization process and reducing the risk of late-stage failure due to ADMET-related issues.

  • Developed by: Swanson K et al.
  • Source: GitHub repository
  • Reference: Swanson K et al. "ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries." Bioinformatics 40(7):btae416, 2024. https://academic.oup.com/bioinformatics/article/40/7/btae416/7698030

在 Vecura 上试用 ADMET-AI

打开模型工作区,用您自己的输入开始评估

试用模型

主题

admetdrug-discoverypharmacokineticstoxicitysmall-moleculechemprop

On this page

What is ADMET-AI?What can users do with ADMET-AI on Vecura?What the output meansWhy this matters
Vecura

产品

  • 定价

公司

  • 联系我们

资源

  • 博客
  • 社区

法律条款

  • 隐私政策
  • 服务条款
  • 信任中心

© 2026 NYB AI 保留所有权利。

所有系统运行正常